Clinical trials: Alzheimer Disease 1
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease, Huntington's Disease
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects.
- Trial name
- NCT00827034
- Testing
- Warfarin, Dimebon
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cognitive Function 1, Social
Evaluating Cognitive and Functional Impairment in Alzheimer's Dementia With a Ketogenic Diet.
The present study is being done in a scientifically rigorous manner, using readily available MCT oil (refined from coconut oil) versus a placebo oil to assess any cognitive and functional benefits for AD patients.
- Trial name
- NCT04396015
- Testing
- Bulletproof Brain Octane
- Volunteers
- 20 people
- Sponsor
- University of Alberta
Alzheimer's Disease
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment.
- Trial name
- Identity XT (NCT01035138)
- Testing
- semagacestat
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
- Trial name
- NCT05532358
- Testing
- anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Alzheimer's Disease
Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).
This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.
- Trial name
- NCT02695004
- Testing
- DKF-310
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Alzheimer Disease
Tricaprilin Liquid Formulation PK Study
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to advance in development.
- Trial name
- NCT05028114
- Testing
- AC-1202, AC-OLE-01, AC-OLE-02
- Where
- Australia
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease, Mild Cognitive Impairment
System-IGF-1 Pathway and Alzheimer's Disease
The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Cognitive Function 1, Social, Control With Normal Activities of Daily Living
- Trial name
- SIGAL (NCT00647478)
- Where
- France
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes, Peripheral Arterial Occlusive Disease
Evaluate the Correlation of NIRS, ABI, Exercise, baPWV and Albuminuria With Peripheral Artery Occlusion Disease (PAD) and Other Atherosclerosis Outcomes
By utilizing Near infrared spectroscopy (NIRS), the local blood flow, tissue oxygenation (StO2), and recovery time of ischemic leg; can be determined.
- Trial name
- NCT03378024
- Testing
- oscillometric (Omron Colin co)
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease
The overall study methods are as follows. [Clinical Trials Schedules] The study consists of a screening period(Visit 1) of up to 30 to 50 days, blood collection visits(Visit 2) for IP generation and administration visits for IP…
- Trial name
- NCT05016427
- Testing
- VT301
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- VTBIO Co. LTD
Healthy, Alzheimer Disease
A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety…
- Trial name
- NCT06343636
- Testing
- VG-3927
- Where
- 3 sites in United States, Australia
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Vigil Neuroscience, Inc.
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer Disease
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants.
- Trial name
- Allo (NCT02221622)
- Testing
- Allopregnanolone injection (intravenous solution)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Healthy
A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377
This study will see how PF-05212377, an experimental drug to treat symptoms from Alzheimer's Disease, distributes in the brain after one dose of PF-05212377 is administered orally to healthy volunteer subjects.
- Trial name
- NCT02005991
- Testing
- PF-05212377
- Where
- 3 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Symptoms, Anxiety Generalized
Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men
The purpose of this study is to determine whether a mobile phone application ("app") for symptoms of depression and anxiety is practical and acceptable to young men who are attracted to men, and whether it reduces their anxiety…
- Trial name
- TODAY! (NCT02072252)
- Testing
- Mobile Phone Application
- Where
- United States
- Sponsor
- Northwestern University
Healthy Volunteers, Down Syndrome
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS)…
- Conditions
- Healthy Volunteers, Down Syndrome, Alzheimer's Disease
- Trial name
- LEUCETTA (NCT06206824)
- Testing
- Leucettinib-21
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Perha Pharmaceuticals
Alzheimer Disease
AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions
This is an open-label, 3-arm study to compare tolerability of three different titration and dosing schedules of the AC-OLE-01-VA formulation of tricaprilin.
- Trial name
- NCT05628636
- Testing
- AC-OLE-01-VA
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA